NCT06834152 (X-SMILE) is a clinical trial of radiotherapy in Localized Prostate Carcinoma, sponsored by University of Zurich.

Who is sponsoring NCT06834152?

NCT06834152 is sponsored by University of Zurich.

What drugs are being tested in NCT06834152?

Interventions in NCT06834152: radiotherapy.

What condition does NCT06834152 study?

NCT06834152 studies Localized Prostate Carcinoma, Prostate Cancer (Adenocarcinoma), Prostate Hyperplasia, Lower Urinary Track Symptoms.

Is NCT06834152 still recruiting?

NCT06834152 is currently recruiting now. Last updated 9 February 2026.

Last reviewed 2026-02-09 · How we verify

NCT06834152: X-SMILE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer (X-SMILE)

Recruiting now Last updated 9 February 2026

What this trial tests

trial testing radiotherapy in Localized Prostate Carcinoma in 75 participants. Currently enrolling.

Timeline

1 March 2024

Primary endpoint
1 September 2026

30 June 2031

Quick facts

Lead sponsor	University of Zurich
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	75
Start date	1 March 2024
Primary completion	1 September 2026
Estimated completion	30 June 2031
Sites	3 locations across Switzerland, Germany

Drugs / interventions tested

radiotherapy — full drug profile →

Conditions studied

Localized Prostate Carcinoma — all drugs for Localized Prostate Carcinoma →
Prostate Cancer (Adenocarcinoma) — all drugs for Prostate Cancer (Adenocarcinoma) →
Prostate Hyperplasia — all drugs for Prostate Hyperplasia →
Lower Urinary Track Symptoms — all drugs for Lower Urinary Track Symptoms →

Sponsor

University of Zurich

Who can join

18 and older, male only, with Localized Prostate Carcinoma or Prostate Cancer (Adenocarcinoma). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this phase II international multicenter study is to evaluate the safety, feasibility, and efficacy of CT or MRI-adaptive SBRT, delivered in five weekly fractions, in patients with newly diagnosed localized prostate cancer who have lower urinary tract symptoms and/or prostatic hyperplasia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Online adaptive stereotactic body radiotherapy for localized prostate cancer in patients with lower urinary tract symptoms and/or prostate hyperplasia (X-SMILE).
Kroese T, Andratschke N, Belka C, Corradini S, et al · · 2025 · PMID 40437508 · DOI 10.1186/s13014-025-02653-4

Verify or expand the search:

Other trials of radiotherapy

Trials testing the same drug.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07527884 — The Effect of Radiotherapy After Separation Surgery for Spinal Metastases · NA · not yet recruiting
NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
NCT07282483 — Traditional Chinese Medicine Oral Liquids and Mouthwashes for Radiation-induced Oral Mucositis in Head and Neck Cancer P · Phase 2 · recruiting
NCT07445048 — Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck · Phase 3 · recruiting

Other recruiting trials for Localized Prostate Carcinoma

Currently open trials in the same condition.

NCT06674863 — Addressing Health Literacy With a Tailored Survivorship Care Plan · NA · recruiting
NCT06940271 — Feasibility and Effect of Wrapping Nerves With a Multi-Layer Perinatal Tissue Allograft During Prostatectomy · NA · recruiting
NCT07054346 — Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 · Phase 1 · recruiting
NCT06733350 — Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer · Phase 4 · recruiting
NCT05665738 — Two-fraction HDR Monotherapy for Localized Prostate Cancer · NA · recruiting

Other University of Zurich trials

Trials by the same sponsor.

NCT07485699 — Soy Processing and Food Allergy · NA · not yet recruiting
NCT07516912 — Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland · not yet recruiting
NCT07473115 — Individualized Analgesia in the Intensive Care Unit With a New Pain Assessment Bundle and Protocolized Analgesia Adjustm · not yet recruiting
NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
NCT06481982 — Value of Advanced MRI Techniques in the Assessment of Endometriosis · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06834152 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Zurich
Last refreshed: 9 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06834152.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing